(1)
- Clinical utility of Axumin (fluciclovine F 18) being investigated in expanded areas of cancer imaging -
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced that the first patient has been dosed in its Phase 3 REVELATE clinical trial of
18F-fluciclovine, a positron emission tomography (PET) imaging radiopharmaceutical being studied for potential use in detecting recurrent brain metastases. The REVELATE study is a Phase 3, multi-center, single-arm imaging study being conducted in the United States. Its purpose is to assess the diagnostic performance of
18F-fluciclovine PET in detecting recurrent brain metastases in patients previously treated with radiation therapy. The first patient dosed in the study was at Yale University, New Haven, Conn., under the auspices of Dr. Mariam Aboian, Assistant Professor of Radiology.
Spain’s IFEMA to host ESTRO annual congress 2021
The European Society of Radiotherapy and Oncology (ESTRO) will bring back face-to-face event business to the halls of
IFEMA in Madrid this August. The venue will host the society’s annual congress, 27-31 August 2021, in its North Convention Centre and Hall 10.
Organisers expect 6,000 radiation oncology professionals to attend the congress, which will have a hybrid format offering online content and streaming broadcasts of the scientific programme. It will be the first time that Madrid will have hosted an ESTRO congress.
ESTRO is working closely with the Spanish Society of Radiation Oncology (SEOR) on the congress, which aims at giving relevance to radiation oncology both in the scientific field and in terms of helping patients benefit from technological and scientific advances.
Virtual care during COVID-19 delivers impressive benefits for cancer patients, clinicians
Patients and healthcare providers at the Princess Margaret Cancer Centre rated virtual care during COVID-19 as highly satisfactory overall for quality of care and convenience, while at the same time-saving patients millions in costs.
Research led by Princess Margaret Radiation Oncologist Dr. Alejandro Berlin showed that virtual care can be implemented rapidly and safely across a highly-specialized and high-volume cancer center. Eighty (80) percent of patients reported they were either very satisfied or satisfied with it, citing convenience as the main factor, with 72 percent of physicians reporting similar satisfaction with it.
Nanobiotix Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering
Nanobiotix will use a portion of the proceeds from the its IPO to launch its global phase III registration study in head and neck cancer in the United States in 2021
Following previously reported preliminary data regarding the ability of NBTXR3 to help transform anti-PD-1 non-responders into responders, the Company will provide the next update on its immuno-oncology phase I basket study evaluating NBTXR3 in combination with anti-PD-1 checkpoint inhibitors in the second quarter of 2021
The Company s expansive global development plan for NBTXR3, both as a single agent activated by radiotherapy and in combination with other anti-cancer therapies, will continue as planned
BREAKING A&E staff nurse first to be vaccinated for Covid-19 at Portlaoise hospital marks historic day in Laois
Reporter:
news@leinsterexpress.ie
Aidel Aurel Casabar, staff nurse ED, is the first person in the Midland Regional Hospital Portlaoise to be vaccinated . She was vaccinated by Mary Gilligan, Clinical Placement Co-ordinator. );
);
A staff nurse at Portlaoise s busy Emergency Department (ED/A&E) is the first person to be vaccinated for Covid-19 in Laois.
Aidel Aurel Casabar received the Pfizer BioNTech Covid-19 vaccine at the Midland Regional Hospital Portlaoise on Thursday, January 7. She was vaccinated by her colleague Mary Gilligan, Clinical Placement Co-ordinator.